Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH
Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in NASH.
For detailed information, see the below URL.
CM-101, a monoclonal antibody designed to bind and block CCL24 activity. The antibody used the STAM™ mouse model for non-clinical studies, and data showing the improvement of NASH and fibrosis in the STAM™ mouse model was published in JHEP Reports.
https://www.sciencedirect.com/science/article/pii/S2589555919301582
In the future, we believe that further clinical trial results for CM-101 will provide evidence for the STAM™ mouse model as a clinically predictive NASH model.